Aerosolised antipsychotic assuages agitation: Inhaled loxapine for agitation associated with schizophrenia or bipolar disorder

International Journal of Clinical Practice

Volumn 65, Issue 3, 2011, Pages 330-340

  Citrome, L ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOXAPINE;

AEROSOL; AGITATION; BIPOLAR DISORDER; DIZZINESS; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FOOD AND DRUG ADMINISTRATION; HUMAN; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, INHALATION; AEROSOLS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; HUMANS; LOXAPINE; NEBULIZERS AND VAPORIZERS; PSYCHOMOTOR AGITATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 79951656747     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02615.x     Document Type: Review

References (21)

1. Citrome L,. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry 2007; 68: 1876-85.
2. Ereshefsky L,. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry 1999; 60 (Suppl. 10): 20-30. (Pubitemid 29237172)
3. Fruensgaard K, Korsgaard S, Jorgensen H, Jensen K,. Loxapine versus haloperidol parenterally in acute psychosis with agitation. A double-blind study. Acta Psychiatr Scand 1977; 56: 256-64. (Pubitemid 8190608)
4. Fruensgaard K, Wollenberg J, Hansen KM, Fensbo C, Sihm F,. Loxapine versus perphenazine in psychotic patients. A double-blind, randomized, multicentre trial. Curr Med Res Opin 1978; 5: 601-7. (Pubitemid 9024527)
5. Fruensgaard K,. Parenteral treatment of acute psychotic patients with agitation: a review. Curr Med Res Opin 1978; 5: 593-600. (Pubitemid 9024526)
6. Spyker DA, Munzar P, Cassella JV,. Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. J Clin Pharmacol 2010; 50: 169-79.
7. Dinh KV, Myers DJ, Noymer PD, Cassella JV,. In vitro aerosol deposition in the oropharyngeal region for Staccato Loxapine. J Aerosol Med Pulm Drug Deliv 2010; 23: 253-60.
8. Allen MH, Feifel DA, Lesem MD, et al. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo controlled trial. J Clin Psychiatry, in press.
9. Lesem MD, Tran-Johnson TK, Riesenberg RA, et al. Rapid acute treatment of agitation in patients with schizophrenia. Results of a multicenter, randomized, placebo-controlled study of inhaled loxapine. Br J Psychiatry, in press.
10. Noymer P, Myers D, Glazer M, Fishman RS, Cassella JV,. The Staccato system: inhaler design characteristics for rapid treatment of CNS disorders. Resp Drug Deliv 2010; 1: 11-20.
11. Nordstrom K,. Inhaled loxapine for acute agitation in schizophrenia and bipolar disorder. Future Neurol 2009; 4: 539-45.
12. Alexza Pharmaceuticals. Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato(R) Loxapine) NDA. Available at: http://nocachephx. corporate-ir.net/phoenix.zhtml?c=196151&p=RssLanding-pf&cat=news&id= 1480909 (accessed 11 October 2010).
13. Citrome L,. Compelling or irrelevant? Using number needed to treat can help decide Acta Psychiatr Scand 2008; 117: 412-9. (Pubitemid 351678479)
14. Citrome L,. Quantifying risk: The role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr Drug Saf 2009; 4: 229-37.
15. Kraemer HC, Kupfer DJ,. Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry 2006; 59: 990-6. (Pubitemid 43849650)
16. Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 11th edn. New York: McGraw-Hill; 2005. Table 18-2, page 472.
17. Watson Laboratories, Inc. Amoxapine Tablet. Product Label, revised July 2010. Available at:http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=19651. Accessed 12 November 2010.
18. Fishman R, Cassella J, Spyker D, AZ-004 Study Group. Inhaled Loxapine Rapidly Improves Acute Agitation in Patients With Bipolar Disorder. Poster presentation, NR7-006. 162nd Annual Meeting of the American Psychiatric Association, San Francisco, California, 2009: 16-21.
19. Cassella J, Spyker D, Kwentus J, Lesem M, Fishman R,. Rapid Improvement in the Five-Item PANSS-EC Scale for Agitation With Inhaled Loxapine (AZ-004). Poster presentation, Session II-34. 50th Meeting of the NCDEU, Boca Raton, Florida, 2010; 14-7.
20. Fishman R, Gottwald M, Cassella J,. Inhaled Loxapine (AZ-004) Rapidly and Effectively Reduces Agitation in Patients With Schizophrenia and Bipolar Disorder. Poster presentation, Session II-15. 13th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, San Antonio, Texas, 2010; 18-21.
21. Fishman R, Spyker D, Cassella J,. The Safety of Concomitant use of Lorazepam Rescue in Treating Agitation With Inhaled Loxapine (AZ-004). Poster presentation, Session I-65. 50th Meeting of the NCDEU, Boca Raton, Florida, 2010; 14-7.